Ashwani Patil | Cancer Biology | Best Scholar Award

Posted on by ScienceFather

Dr. Ashwani Patil | Cancer Biology | Best Scholar Award

Assistant Professor, Dr. D. Y. Patil Institute of Pharmaceutical Sciences & Research India

Dr. Ashwani Patil is a passionate pharmacologist specializing in neurological disorders and cancer research. He completed his Ph.D. in Pharmacology from the Institute of Chemical Technology (ICT), Mumbai, with a focus on preclinical drug development. His research at Bhabha Atomic Research Centre and NIRRH Mumbai deepened his expertise in molecular mechanisms underlying complex diseases. With hands-on experience in animal handling, molecular techniques, and pharmacological testing, he has contributed significantly to understanding disease pathology and potential therapeutic targets for cancer and neurological disorders.

Professional Profile 

Scopus

Scholar

🎓Education

Ph.D. in Pharmaceutical Tech. (Pharmacology), Institute Of Chemical Technology, Mumbai (2024). M. Pharmacy (Pharmacology), R. C. Patel Institute of Pharmaceutical Education and Research, Shirpur (2018). Bachelor of Pharmacy, A.R.A College of Pharmacy, Dhule (2016)

💼Experience

Junior Research Fellow, R.C. Patel Institute of Pharmaceutical Education and Research, Shirpur (2018-2019). Research Scholar, Institute of Chemical Technology, Mumbai (2022-Present). Assistant Professor, Dr. D Y Patil Institute of Pharmaceutical Science and Research, Pune (2019-2020, 2024). Expertise in preclinical drug studies, rodent surgery, data analysis, and project planning.

🏆Award and Honor

DAE-ICT Fellowship, 2024. 1st Position in Poster Presentation, 7th International Conference on “Emerging Trends in Drug Development and Delivery” (2024). Research Excellence Award, GEU, Dehradun (2015). Best Paper Presentation Award, TriboIndia 2023, NIT Srinagar

🔬 Research Focus

Dr. Patil’s research spans preclinical drug development, focusing on neurological disorders and cancer. His work investigates therapeutic targets, pharmacodynamics, and the molecular mechanisms of disease pathology. Key areas of interest include rodent models, drug efficacy, safety profiles, and mitochondrial toxicity. His publications highlight cancer cell cytotoxicity and cardioprotective effects, contributing to the understanding of pharmacological agents in disease treatment.

Publications Top Noted

1. Title: Cardioprotective effect of CB1 receptor antagonist AM251 against β receptor-stimulated myocardial infarction via modulation of NF-kB signaling pathway in diabetic mice

Year: 2024
Authors: Pawar, H.D., Patil, Y., Patil, A., Ojha, S., Goyal, S.N.
Citation: Heliyon, 10(15), e35138
Citations: 0

2. Title: Mitochondria-targeted derivative of pterostilbene, a dietary phytoestrogen, exhibits superior cancer cell cytotoxicity via mitochondrial superoxide mediated induction of autophagy

Year: 2023
Authors: Ibrahim, M.K., Nandha, S.R., Patil, A.S., Sharma, D., Sandur, S.K.
Citation: Advances in Redox Research, 8, 100071
Citations: 1

3. Title: Mitochondriotropic Derivative of Ethyl Ferulate, a Dietary Phenylpropanoid, Exhibits Enhanced Cytotoxicity in Cancer Cells via Mitochondrial Superoxide-Mediated Activation of JNK and AKT Signalling

Year: 2023
Authors: Patil, A.S., Ibrahim, M.K., Sathaye, S., Sharma, D., Sandur, S.K.
Citation: Applied Biochemistry and Biotechnology, 195(3), 2057–2076
Citations: 2

4. Title: Plant-derived natural therapeutics targeting cannabinoid receptors in metabolic syndrome and its complications: A review

Year: 2020
Authors: Patil, A.S., Mahajan, U.B., Agrawal, Y.O., Sharma, C., Goyal, S.N.
Citation: Biomedicine and Pharmacotherapy, 132, 110889
Citations: 17

5. Title: Protective effect of omeprazole and lansoprazole on β-receptor stimulated myocardial infarction in Wistar rats

Year: 2019
Authors: Patil, A.S., Singh, A.D., Mahajan, U.B., Ojha, S., Goyal, S.N.
Citation: Molecular and Cellular Biochemistry, 456(1-2), 105–113
Citations: 17

 

Somnath Paul | Cancer Immunotherapy | Best Researcher Award

Posted on by ScienceFather

Dr. Somnath Paul | Cancer Immunotherapy | Best Researcher Award

Staff Scientist, Washington University United States

Somnath Paul, Ph.D., is a Staff Scientist in the Department of Pathology and Immunology at Washington University in St. Louis, MO. With a robust academic and research career, he specializes in molecular genetics, epigenetics, and immunology. Over the years, Dr. Paul has contributed significantly to cancer research, developing new strategies for tumor profiling and immunotherapy. He has worked at prestigious institutions like the University of Texas MD Anderson Cancer Center and CSIR-Indian Institute of Chemical Biology, publishing several key research articles.

Profile

Scopus

Scholar

🎓 Education

Dr. Paul earned his Ph.D. in Molecular and Human Genetics from Jadavpur University, India (2016), after completing a Master’s in Genetics at the University of Calcutta (2008). He began his academic journey with a Bachelor’s in Physiology from Presidency College, University of Calcutta (2006). His educational foundation laid the groundwork for his research focus on epigenetics, immunology, and cancer biology.

💼 Experience

Dr. Paul’s professional career spans prestigious institutions, including Washington University (2024–Present), University of Texas MD Anderson Cancer Center (2020–2024), and CSIR-Indian Institute of Chemical Biology (2009–2016). His work focuses on immunotherapy, monoclonal antibody production, and the genetic regulation of cancer. He has been a postdoctoral fellow, research scientist, and project assistant, contributing to several groundbreaking research projects in molecular biology, toxicology, and immunology.

🏆 Awards and Honors

Dr. Paul has received notable accolades, such as the prestigious NIH-funded research project on INO80 chromatin remodeling. He was also honored with research excellence awards, including one from GEU, DDN in 2015, and the Early Career Research Award from SERB (2017). Additionally, he received travel grants from DST (2012) and presented a best paper at TriboIndia-2023 Conference.

🔬 Research Focus

Dr. Paul’s research is primarily centered on understanding tumor progression through circulatory tumor cell profiling, tumor remission and relapse monitoring, and novel monoclonal antibody development for immunotherapy. His work includes studying the infection dynamics of herpes viruses, epigenetic mechanisms of cancer, and identifying biomarkers for early disease detection. He aims to enhance therapeutic strategies through innovative platforms and experimental models.

🏆 Conclusion

Dr. Somnath Paul is a strong contender for the Best Researcher Award due to his robust academic and research portfolio, innovative contributions, and extensive publication record. Addressing the identified areas for improvement could further bolster his candidacy for this and similar accolades in the future.

Publication

  1. Arsenic exposure through drinking water increases the risk of liver and cardiovascular diseases in the population of West Bengal, India
    Year: 2012
    Authors: N Das, S Paul, D Chatterjee, N Banerjee, NS Majumder, N Sarma, TJ Sau, …
    Citations: 150

 

  1. Functional compensation of glutathione S-transferase M1 (GSTM1) null by another GST superfamily member, GSTM2
    Year: 2013
    Authors: P Bhattacharjee, S Paul, M Banerjee, D Patra, P Banerjee, N Ghoshal, …
    Citations: 104

 

  1. Loss of Snf5 Induces Formation of an Aberrant SWI/SNF Complex
    Year: 2017
    Authors: P Sen, J Luo, A Hada, SG Hailu, ML Dechassa, J Persinger, S Brahma, …
    Citations: 99

 

  1. The Arp8 and Arp4 module acts as a DNA sensor controlling INO80 chromatin remodeling
    Year: 2018
    Authors: S Brahma, M Ngubo, S Paul, M Udugama, B Bartholomew
    Citations: 81

 

  1. Arsenic-induced toxicity and carcinogenicity: a two-wave cross-sectional study in arsenicosis individuals in West Bengal, India
    Year: 2012
    Authors: S Paul, N Das, P Bhattacharjee, M Banerjee, JK Das, N Sarma, A Sarkar, …
    Citations: 78

 

  1. Arsenic-induced promoter hypomethylation and over-expression of ERCC2 reduces DNA repair capacity in humans by non-disjunction of the ERCC2/Cdk7 complex
    Year: 2014
    Authors: S Paul, N Banerjee, A Chatterjee, TJ Sau, JK Das, PK Mishra, …
    Citations: 65

 

  1. Recent advances in arsenic research: significance of differential susceptibility and sustainable strategies for mitigation
    Year: 2020
    Authors: T Sanyal, P Bhattacharjee, S Paul, P Bhattacherjee
    Citations: 62

 

  1. Epimutagenesis: A prospective mechanism to remediate arsenic-induced toxicity
    Year: 2015
    Authors: S Paul, AK Giri
    Citations: 52

 

  1. Risk of Occupational exposure to Asbestos, Silicon and Arsenic on Pulmonary Disorders: Understanding the Genetic-Epigenetic Interplay and Future Prospects.
    Year: 2016
    Authors: P Bhattacharjee, S Paul, P Bhattacharjee
    Citations: 47

 

  1. Epigenetic Modifications of DAPK and p16 Genes Contribute to Arsenic-Induced Skin Lesions and Non-Dermatological Health Effects
    Year: 2013
    Authors: N Banerjee, S Paul, TJ Sau, JK Das, A Bandyopadhyay, AK Giri
    Citations: 44

 

 

Portia Smallbone | Stem Cell Transplantation | Young Scientist Award

Posted on by ScienceFather

Dr. Portia Smallbone | Stem Cell Transplantation | Young Scientist Award

Assistant Professor, MD Anderson Cancer Center, United States

Dr. Portia Smallbone is a clinical and laboratory haematologist from Perth, Western Australia. She currently serves as an Assistant Professor in Stem Cell Transplant and Cellular Therapy at MD Anderson Cancer Center in Houston, Texas. With extensive experience in clinical haematology, laboratory medicine, and stem cell transplantation, Dr. Smallbone’s research focuses on innovative treatments for hematological conditions. She has contributed to several high-impact publications and actively mentors medical trainees.

Publication Profile

Scopus

Orcid

🎓 Education

Bachelor of Medicine and Surgery (MBBS, Hons): University of Western Australia (2015). Professional Fellowships: Fellow of Royal Australian College of Physicians (FRACP, 2023) and Royal Australian College of Pathologists (FRCPA, 2023). Licenses: Texas Medical License (BP10085156), ECFMG Certification, AHPRA License (IMED0002069900).

💼 Experience

Assistant Professor: MD Anderson Cancer Center (2023–Present). Clinical & Laboratory Haematology Fellowship: Fiona Stanley Hospital, Perth, WA (2020–2023). Chief Resident: Fiona Stanley Hospital (2020–2021). Internship & Residency: Sir Charles Gairdner Hospital, Perth (2016–2019).

🏅 Awards & Honors

Travel Grant: ASTCT Conference (2024). Spinnaker Health Research Grant: $20,000 (2022). Junior Medical Officer of the Month: Hollywood Hospital (2017). Academic Excellence: Coral Haughie Memorial Prize, RANZCOG OB/GYN Award (2014).

🔬 Research Focus

Dr. Smallbone’s research interests include graft-versus-host disease, hematopoietic stem cell transplantation outcomes, and novel therapies for hematological malignancies. She is involved in studies exploring cfDNA applications in myelofibrosis, the efficacy of decitabine in leukemia, and chronic GVHD management.

 Conclusion

Dr. Portia Smallbone is a highly accomplished and dedicated researcher with outstanding contributions to hematology. Her extensive academic achievements, research outputs, and leadership roles position her as a strong contender for the Young Scientist Award. With continued efforts to expand collaborations and focus on translational outcomes, she can further solidify her impact as a leader in the field.

Publication Top Notes

  • Hematopoietic Stem Cell Transplantation in Patients With Myelofibrosis and Splanchnic Vein Thrombosis: A Case Series
    • Year: 2024-12-09
    • Authors: Portia Smallbone; Mallika Sekhar; Samer A. Srour; Jeremy L. Ramdial; Crystal L. Carmicheal Kusy; Elizabeth J. Shpall; Uday R. Popat
    • Citation: American Journal of Hematology
    • DOI: 10.1002/ajh.27542

 

  • Gastrointestinal Involvement Refines Prognosis in Minnesota Standard Risk Acute Graft-Versus-Host Disease
    • Year: 2024-11
    • Authors: Curtis M. Marcoux; Amin Alousi; Jin Im; Laquisa C. Hill; Portia Smallbone; Uday Popat; Chitra Hosing; Partow Kebriaei; Amanda Olson; Rohtesh Mehta et al.
    • Citation: Bone Marrow Transplantation
    • DOI: 10.1038/s41409-024-02393-1

 

  • Central Nervous System Manifestations in Acute and Chronic Graft-Versus-Host Disease
    • Year: 2024-10-23
    • Authors: Nicolas Lambert; Florence Forte; Majdouline El Moussaoui; Justine Monseur; Nicole Raus; Alexey Polushin; David Michonneau; Carl Shultz; William J. Hogan; Aitana Balaguer-Roselló et al.
    • Citation: Brain
    • DOI: 10.1093/brain/awae340

 

  • Laboratory Methods of Monitoring Disease Response After Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis

 

  • The Clinical Features, Management, and Outcomes of Lymphoma in Pregnancy: A Multicenter Study by the Australasian Lymphoma Alliance
    • Year: 2023-06
    • Authors: Pietro Di Ciaccio; Georgia Mills; Michael J. Shipton; Belinda A. Campbell; Gareth Peter Gregory; Jenna Langfield; Matthew Greenwood; Sean McKeague; Mohammad Shanavas; Renee Eslick et al.
    • Citation: British Journal of Haematology
    • DOI: 10.1111/bjh.18727

 

  • EBV-Associated Diffuse Large B Cell Lymphoma Arising Within Atrial Myxoma in an Immunocompetent Patient Can Be Treated Successfully With Surgery Alone
    • Year: 2020-04
    • Authors: Portia Smallbone; Benhur Amanuel; Peter D. Robbins; Jurgen Passage; Carolyn S. Grove
    • Citation: Pathology
    • DOI: 10.1016/j.pathol.2020.01.678

 

  • Clinically Significant Pleural Effusion in Intensive Care: A Prospective Multicenter Cohort Study
    • Year: 2020-01
    • Authors: Edward T. H. Fysh; Portia Smallbone; Nicholas Mattock; Cassandra McCloskey; Edward Litton; Bradley Wibrow; Kwok M. Ho; Y. C. Gary Lee
    • Citation: Critical Care Explorations
    • DOI: 10.1097/cce.0000000000000070

 

  • Prognostic Factors and the Impact of Frontline Therapy in Peripheral T-Cell Lymphoma: 10 Years of ‘Real-World’ Experience From Western Australia
    • Year: 2019-12-06
    • Authors: James A. Kuzich; Andrew P. Hutchison; Kenneth J. C. Lim; Portia Smallbone; Kate Denning; Matthew P. Wright; Gavin Cull; Michael F. Leahy; David J. L. Joske; Dejan Radeski et al.
    • Citation: Leukemia & Lymphoma
    • DOI: 10.1080/10428194.2019.1637865

 

Mi Rim Lee |cancer science Award | Young Scientist Award

Posted on by ScienceFather

Ms. Mi Rim Lee| Genomics Award | Young Scientist Award

👨‍🏫Profile Summary

John Doe is a dedicated Ph.D. candidate in Cancer Biomedical Science at the National Cancer Center Graduate School of Cancer Science and Policy. With a solid academic background in Biomaterials, he obtained both his Master’s and Bachelor’s degrees from Pusan National University. John’s achievements include prestigious scholarships and poster awards from esteemed institutions like the Korean Society of Laboratory Animal Science and the Korean Cancer Association. His research interests lie at the intersection of cancer biology and biomaterials, aiming to contribute novel insights into cancer treatment and therapy development. John’s academic excellence and commitment to cancer research mark him as a promising young scientist in the field.

🌐 Professional Profiles

Education🎓

2019.09~present: National Cancer Center Graduate School of Cancer Science and Policy Major: Cancer Biomedical Science Degree: Ph.D. candidate, 2017.03~2019.02: Pusan National University Major: Biomaterial Degree: MS. 2011.03~2017.02: Pusan National University Major: Biomaterial Degree: BA.

Awards 🏆

2018.02: Title: Scholarship Student Institution: Korean Society of Laboratory Animal Science 2018.07: Title: Poster Award Institution: Korean Society of Laboratory Animal Science 2019.01: Title: Academic Award Institution: College of Life and Resources Sciences, Pusan National University 2021.06: Title: Poster Award Institution: Korean Cancer Associati

📚Top Noted Publication

  1. Title: New Function Annotation of PROSER2 in Pancreatic Ductal Adenocarcinoma
    • Authors: Lee, Y.-S., Im, J., Yang, Y., … Hwang, H., Kim, Y.-H.
    • Journal: Journal of Proteome Research
    • Publication Year: 2024
    • Volume: 23
    • Issue: 3
    • Pages: 905–915

 

  1. Title: Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer
    • Authors: Lee, M.R., Woo, S.M., Kim, M.K., … Kim, Y.-H., Kong, S.-Y.
    • Journal: Cancer Science
    • Publication Year: 2024

 

  1. Title: Complexation of drug and hapten-conjugated aptamer with universal hapten antibody for pancreatic cancer treatment
    • Authors: Choi, S.I., Lee, Y.-S., Lee, Y.M., … Kim, Y.-H., Kim, I.-H.
    • Journal: Journal of Controlled Release
    • Publication Year: 2023
    • Volume: 360
    • Pages: 940–952

 

  1. Title: Refining Classification of Cholangiocarcinoma Subtypes via Proteogenomic Integration Reveals New Therapeutic Prospects
    • Authors: Cho, S.Y., Hwang, H., Kim, Y.-H., … Park, S.-J., Woo, S.M.
    • Journal: Gastroenterology
    • Publication Year: 2023
    • Volume: 164
    • Issue: 7
    • Pages: 1293–1309

 

  1. Title: Establishment of Patient-Derived Organoids Using Ascitic or Pleural Fluid from Cancer Patients
    • Authors: Choi, W., Kim, Y.-H., Woo, S.M., … Lee, K.S., Kong, S.-Y.
    • Journal: Cancer Research and Treatment
    • Publication Year: 2023
    • Volume: 55
    • Issue: 4
    • Pages: 1077–1086

 

  1. Title: Establishment of Patient-derived Preclinical Models for Invasive Papillary Cholangiocarcinoma
    • Authors: Mwesige, B., Lee, M.R., Lee, Y.-S., … Woo, S.M., Kim, Y.-H.
    • Journal: Anticancer Research
    • Publication Year: 2022
    • Volume: 42
    • Issue: 1
    • Pages: 599–608